Detalles de la búsqueda
1.
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
Int J Cancer
; 151(4): 637-648, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35429348
2.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Gynecol Oncol
; 164(3): 505-513, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35063281
3.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33931498
4.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462317
5.
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Int J Cancer
; 147(2): 565-574, 2020 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32096871
6.
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Support Care Cancer
; 28(5): 2435-2442, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048043
7.
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Br J Cancer
; 121(7): 584-592, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31434988
8.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Br J Cancer
; 121(9): 744-750, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31537908
9.
Efficacy and safety of niraparib as maintenance treatment in older patients (≥â¯70â¯years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 152(3): 560-567, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30638768
10.
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
BMC Cancer
; 17(1): 366, 2017 05 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28545541
11.
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Gynecol Oncol
; 144(2): 256-259, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27993479
12.
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.
Proteomics
; 15(2-3): 365-73, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25311472
13.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
J Clin Oncol
; 42(13): 1488-1498, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38315944
14.
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.
J Transl Med
; 11: 162, 2013 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23819652
15.
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Clin Chem Lab Med
; 51(9): 1815-24, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24013103
16.
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
JCO Precis Oncol
; 7: e2200555, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37364234
17.
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
J Exp Clin Cancer Res
; 42(1): 83, 2023 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041632
18.
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.
Clin Chem Lab Med
; 50(12): 2189-98, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23096757
19.
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma.
Cancers (Basel)
; 14(21)2022 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36358847
20.
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
Front Immunol
; 12: 690201, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34220848